Garrett McClenny, MD
Pulmonary Disease · Mobile, ALNPI 1538746433
Payments from drug & device makers
Across 35 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$264
- Merck$143
- Sanofi$119
- United Therapeutics Corporation$82
- Boehringer Ingelheim$37
- AstraZeneca$29
- plus $168 from 9 others
What the payments were for
- Food & beverage$75389%
- Education$9011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 10 | $264 |
| Merck | 7 | $143 |
| Sanofi | 3 | $119 |
| United Therapeutics Corporation | 3 | $82 |
| Boehringer Ingelheim | 2 | $37 |
| AstraZeneca | 1 | $29 |
| Amgen | 1 | $25 |
| Liquidia Technologies, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Pfizer | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
How this compares
$843 in reported general payments places this provider in the 30th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 20 | $22,010 |
| Omeprazole | 26 | $377 |
| Atorvastatin Calcium | 25 | $164 |
| Amlodipine Besylate | 16 | $78 |
| Losartan Potassium | 11 | $57 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Mobile
- Allan SeibertMobile$2.4M
- Adrian DivittorioMobile$212K
- Peter LutzMobile$102K
- Johnson HaynesMobile$50K
- Virginia RadcliffMobile$23K
- Brian FoutyMobile$21K
- Cynthia CrowderMobile$20K
- Philip AlmaloufMobile$14K
- Campbell SindelMobile$14K
- Chibuzo OdigweMobile$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.